Effect of sphingosine kinase modulators on interleukin-1β release, sphingosine 1-phosphate receptor 1 expression and experimental autoimmune encephalomyelitis.

ABSTRACT:

Background and purpose

The sphingosine analogue, FTY720 (Gilenya^R ), alleviates clinical disease progression in multiple sclerosis. Here, we variously assessed the effects of an azide analogue of (S)-FTY720 vinylphosphonate (compound 5; a sphingosine kinase 1 activator), (R)-FTY720 methyl ether (ROMe, a sphingosine kinase 2 inhibitor) and RB-020 (a sphingosine kinase 1 inhibitor and sphingosine kinase 2 substrate) on IL-1β formation, sphingosine 1-phosphate levels and expression of S1P₁ receptors. We also assessed the effect of compound 5 and ROMe in an experimental autoimmune encephalomyelitis (EAE) model in mice.

Experimental approach

We measured IL-1β formation by macrophages, sphingosine 1-phosphate levels and expression levels of S1P₁ re

SUBMITTER: Barbour M 

PROVIDER: S-EPMC5192795 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature